경영·경제 질문은 AI 비서에게,
무엇이든 물어보세요.
로그인 후 질문을 입력해주세요
소개영상보기
Public Health
Hair Loss Recognized as Disease from Follicle Damage
In recent academic discourse, there is growing recognition of hair loss as a disease of modern people. Getty Images Bank After President Lee Jae-myung stated during the Ministry of Health and Welfare’s year-end 2025 policy briefing that “hair loss is a matter of survival,” controversy has reignited in political circles over whether hair loss treatment should be covered by the National Health Insur
2026.02.02
MedTech
Celltrion Internalizes Hyaluronidase SC Formulation Technology
2026.02.02
MedTech
OLED “Hair-Loss Cap” Claims 92% Cell Aging Cut
2026.02.01
MedTech
Korean Team Develops Light-Based Cancer Cell Therapy
2026.02.06
Global Business
Korea United Pharm speeds Vietnam push, targets double cancer drug sales
2026.02.05
Recent Articles
-
Pharmaceutical R&DSK Bioscience Launches Integrated R&D-to-Production Control Tower(From left) COO Park Jin-sun, Andong L House Plant Manager Lee Sang-yoon, QE Head Lee Beom-han SK bioscience announced on the 21st that it has created the position of Chief Operating Officer (COO), who oversees the company-wide value chain, and appointed Park Jin-sun, Head of Marketing & Business De2026.01.21 -
SK BioscienceSK Bioscience Opens Songdo Era, Launches Global R&D CenterSK bioscience is commencing full-scale operation of the country’s largest global Research & Process Development (R&PD) center, which it has established in Songdo. On the 19th, SK bioscience announced that it has completed the relocation of its headquarters and research institute to the global R&PD c2026.01.19 -
Pharmaceutical R&DK-Bio Shines at JPM as Samsung, Celltrion PresentJP Morgan Healthcare Conference (JPMHC) The JP Morgan Healthcare Conference (JPMHC), the world’s largest pharmaceutical and biotech investment conference with participation from more than 500 companies worldwide, concluded in San Francisco, United States, on the 15th (local time). The combined marke2026.01.19 -
Pharmaceutical R&DCelltrion’s Zymfentra Named Preferred Drug by Major U.S. InsurerCelltrion announced on the 19th that its infliximab subcutaneous (SC) formulation therapy “Zymfentra” has been listed as a preferred drug on the formulary of Evernorth Health Services in the United States. The listing has been applied since January 1 of this year.Evernorth Health Services is a healt2026.01.19 -
Pharmaceutical R&DSamsung Biologics Expands CDMO, Targets Complex BispecificsLee Sang-myeong, Head of CDO Development at Samsung Biologics, explains the business status at a CDO Business Division briefing held in San Francisco, USA, on the 15th (local time). Provided by Samsung Biologics Samsung Biologics is moving away from a contract manufacturing organization (CMO)-center2026.01.18 -
Medical / ResearchKorean Team: Blood Test Predicts Dementia 10 Years AheadCover of the January issue of “Alzheimer‘s & Dementia,” a leading international journal in the field of dementia and Alzheimer’s disease, which published the findings of the Gwangju Dementia Cohort Research Group. Provided by Chosun University Research conducted by a Korean team has found that t2026.01.16 -
Investment / BioAlteogen, Which Licensed Tech to MSD, Teases Big Deal Next WeekOn the 15th (local time), at the JP Morgan Healthcare Conference (JHMHC), the world’s largest pharmaceutical and biotech investment event held in San Francisco, USA, newly appointed Alteogen CEO Jeon Tae-yeon delivers a corporate presentation in the Asia-Pacific (APEC) track. Provided by Alteogen Al2026.01.16 -
Pharmaceutical R&DLG Chem Secures Asia Rights to 96-Hour Painkiller ExparelLG Chem is introducing a long-acting analgesic that can manage pain in surgical patients for a longer duration.LG Chem announced on the 16th that it has signed an exclusive distribution agreement for Asia with Pacira BioSciences (hereinafter Pacira), a U.S. biotech company specializing in pain manag2026.01.16 -
Global ExpansionGCCL, OPIS Sign MOU to Boost Global TrialsThe clinical trial sample analysis organization GCCL has signed a strategic business agreement (MOU) with global contract research organization (CRO) OPIS Research CRO.GCCL announced on the 15th that it had signed an MOU with OPIS on cooperation in global clinical trial operations during the 2026 JP2026.01.16 -
Drug DevelopmentSamsung Moves Aggressively Into Drug DevelopmentSamsung is moving into full-scale new drug development. Samsung Epis Holdings, established last year through a spin-off from Samsung Biologics, has unveiled a “roadmap” to launch Phase 1 clinical trials of a new drug candidate in the United States and Korea within this year. At the J.P. Morgan Healt2026.01.16
